CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third ...

CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical ...

Some genetic diseases leave cells without a crucial protein. One possible treatment is to persuade genes already inside those ...

CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Application of the high-precision technique is part of a clinical trial to treat a genetic disease that can cause liver and ...

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ...

WIRED is obsessed with what comes next. Through rigorous investigations and game-changing reporting, we tell stories that don’t just reflect the moment—they help create it. When you look back in 10, ...

CRISPR screening identified 17 genes and 13 genomic regions associated with red blood cell density, revealing new regulatory ...

CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026.

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

CRISPR Therapeutics AG reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported revenue was USD 12.67 million compared to ...